Table 2. Table 2 provides the incidence of delirium and secondary outcomes in the groups receiving propofol, dexmedetomidine, acetaminophen, and no acetaminophen respectively.
Propofol | Dexmedetomidine | Acetaminophen | No Acetaminophen | |
---|---|---|---|---|
Incidence of Delirium
% (n/N) |
33.3 (2/6) | 50 (3/6) | 16.7 (1/6) | 66.7 (4/6) |
Mean Delirium duration
[n days] |
0.5 | 1 | 0.5 | 1 |
Opioid consumption
mean [SD] * |
8.2 [2.02] | 11.46 [4.2] | 7.54 [2.15] | 12.12 [4.06] |
Time to extubation (mins)
mean [SD] |
410.67 [320.25] | 439 [239.32] | 499.5 [304.63] | 350.17 [232.66] |
Length of stay (days)
mean [SD] |
5.67 [0.82] | 8.5 [6.5] | 7.83 [6.52] | 6.33 [1.97] |
Adverse events | 0 | 1 | 0 | 1 |
Dexmedetomidine dose
mean [SD] ** |
N/A | 0.95 [0.36] | N/A | N/A |
Propofol dose
mean [SD] *** |
43.33 [5.16] | N/A | N/A | N/A |
*Opioid consumption is expressed in hydromorphone equivalent
**Mean dexmedetomidine dose is expressed as infusion rate of mcg/kg/hr
***Mean propofol dose is expressed as infusion rate of mcg/kg/min